Clinical trials
Tolerance clinical trials
Below are recruiting tolerance clinical trials, each written for real people, not researchers. We’re tracking 942 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07102342RecruitingPhase 1/Phase 2
Cell therapy for Parkinson's disease
This trial tests a new cell treatment for Parkinson's disease. It involves injecting special cells into the brain to see if they can safely replace damaged cells and improve symptoms. It might help people who have had Parkinson's for several years and still respond well to medication.
New York, New YorkAges 30–75 - NCT07098663RecruitingPhase 2
Study of MKP10241 for weight loss and diabetes control
This study tests an investigational drug called MKP10241 in healthy people, people with obesity, and people with type 2 diabetes. It aims to see how the drug affects blood sugar, weight, and overall safety. It may be an option if you have obesity or type 2 diabetes managed by diet and/or metformin.
Bayswater, VictoriaAges 18–60 - NCT06161415RecruitingPhase 1
Laquinimod eye drops before vitrectomy: safety study
This trial tests a new eye drop called Laquinimod for people who are already scheduled for a vitrectomy. The drops are given before surgery to see if they are safe and how they spread in the eye.
Palo Alto, CaliforniaAges 18 years+ - NCT07095127RecruitingPhase 2
Testing NVG-2089 for immune thrombocytopenia
This trial tests an investigational drug called NVG-2089 for adults with persistent or chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets. The goal is to see if it safely raises platelet counts and improves bleeding symptoms.
Washington D.C., District of ColumbiaAges 18–80 - NCT07092423Recruiting
Special liquid tube feed for brain injury patients
This study tests a special liquid formula (semi-elemental nutrition) given through a feeding tube to people with severe traumatic brain injury. It aims to see if this formula is easier on the stomach and causes fewer digestive problems than standard tube feeds.
Xi'an, ShaanxiAges 18–75 - NCT05182697Recruiting
Study of SCI-210 for autism-related behavior in kids
This trial tests SCI-210, a cannabis-based medicine, to see if it is safe and can improve challenging behaviors in children and young adults with autism. You may be asked to complete regular check-ins about behavior and development over the study.
BeershebaAges 5–18 - NCT05394831RecruitingPhase 1/Phase 2
Study of an EGFR-targeted drug for advanced lung cancer
This trial tests a new drug (JIN-A02) in people with advanced or metastatic non-small cell lung cancer (NSCLC) whose cancer has specific EGFR mutations. It mainly checks whether the treatment is safe and tolerable, and how the body handles the drug, with possible benefit depending on your mutation type.
Orange, CaliforniaAges 18 years+ - NCT07085507RecruitingPhase 1/Phase 2
Testing a new drug for multiple sclerosis in healthy people and MS patients
This trial tests an experimental oral drug called VT7208 in both healthy volunteers and people with multiple sclerosis (MS). The goal is to see if it is safe and how the body processes it, which could lead to a new treatment option for MS.
Adelaide, South AustraliaAges 18–65 - NCT07077434RecruitingPhase 1
Study of Navlimetostat for advanced solid tumors with specific gene change
This trial tests a new drug, Navlimetostat (BMS-986504), for people with advanced solid tumors that have a specific genetic change called MTAP deletion or loss. It looks at safety, side effects, and how the drug works in the body.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06474442RecruitingPhase 2
BD111 gene therapy for herpes simplex virus eye infection
This trial tests a new gene therapy called BD111 for people with a herpes simplex virus infection in the cornea (the clear front part of the eye). It aims to see if the treatment is safe and can help clear the virus, possibly improving vision.
Wenzhou, ZhejiangAges 18–70 - NCT05425810Recruiting
Smart tool to help check prosthetic socket fit
This study tests an easy-to-use smart system (called ENABLE) that helps assess whether a prosthetic socket fits your leg well. It may help improve comfort and reduce skin problems by making sure the socket fit is assessed in a consistent, affordable way.
Raleigh, North CarolinaAges 18–99 - NCT07070999RecruitingPhase 1/Phase 2
Gene therapy GB221 for infants with SMA type 1
This trial tests a new gene therapy called GB221 for infants with SMA type 1, a rare muscle-weakening disease. It aims to see if this treatment can improve muscle strength and development, and it is for babies who have not had prior gene therapy.
Porto Alegre, Rio Grande do SulAges 2 weeks–1 year - NCT07073833RecruitingPhase 1
IBR900 cell therapy for relapsed/refractory B-cell lymphoma
This trial tests a new cell therapy (IBR900) for people with a type of B-cell lymphoma that has come back or not responded to prior treatments. The therapy uses your own immune cells to target and kill the cancer cells.
Hangzhou, ZhejiangAges 18 years+ - NCT07073547RecruitingPhase 1
Study of AZD0120 for multiple myeloma patients
This trial tests a new drug, AZD0120, in people with multiple myeloma. It aims to find the right dose and see how safe and effective it is. The study includes both newly diagnosed and early relapsed patients.
Phoenix, ArizonaAges 18 years+ - NCT07073638RecruitingPhase 2
Testing a new TB drug called RESP30TB in people with newly diagnosed TB
This trial tests a new drug, RESP30TB, to see if it is safe, tolerable, and can quickly kill TB bacteria in people with newly diagnosed, rifampicin-susceptible pulmonary TB. You may be eligible if you can produce sputum and meet other health criteria.
Cape Town, BellvilleAges 18–65 - NCT05180578Recruiting
Goat milk protein study for children with milk-triggered esophagus inflammation
This trial tests whether goat milk protein is tolerated and safe for kids with eosinophilic esophagitis (EoE) whose symptoms improve when cow milk is stopped and come back when cow milk is added again. It may help some families find an alternative to cow milk, but you must meet specific “milk trigger” and allergy-safety requirements.
JerusalemAges Up to 18 years - NCT05541822RecruitingPhase 2
Study drug for lung cancer with specific c-MET changes
This Phase 2 study tests ABN401 to see how well it works and how safe it is for people with advanced non-small cell lung cancer (NSCLC) that has certain c-MET (a protein) changes. It may help some tumors that have not responded well to prior treatment, especially certain EGFR-related cases.
Lake City, FloridaAges 18 years+ - NCT07058779RecruitingPhase 1
Safety study of SSS55 in healthy volunteers
This trial is testing a new medicine called SSS55 in healthy adults to see if it is safe and how the body processes it. Participants will receive meningococcal and pneumococcal vaccines before the study.
Shanghai, Shanghai MunicipalityAges 18–45 - NCT07063251RecruitingEarly Phase 1
Gene therapy safety study for Stargardt disease in teens
This study tests a new gene therapy called HG005 for Stargardt disease in young people aged 6 to 17. It aims to see if the treatment is safe and tolerable, and how well it works.
ShanghaiAges 6–17 - NCT07058662RecruitingPhase 1/Phase 2
Gene therapy study for Duchenne muscular dystrophy in boys 4-8
This study tests a new gene therapy called BBM-D101 for boys with Duchenne muscular dystrophy. The goal is to see if it is safe and can help improve muscle function. It is for boys aged 4 to 8 who can still walk.
Beijing, Beijing MunicipalityAges 4–9 - NCT07061288RecruitingPhase 1
Testing a new injectable medicine for schizophrenia
This trial tests a new injectable form of KarXT for schizophrenia. It aims to see if the medicine is safe, tolerable, and how it works in the body.
Los Alamitos, CaliforniaAges 18–55 - NCT07060989RecruitingPhase 1/Phase 2
Study of NTS071 for advanced solid tumors with TP53 Y220C mutation
This trial tests a new drug called NTS071 in people with advanced solid tumors that have a specific mutation in the TP53 gene (called Y220C). The goal is to see if the drug is safe and can help shrink or slow the growth of the tumor.
Houston, TexasAges 18 years+ - NCT06988670RecruitingPhase 2
Testing EXT608 for adults with hypoparathyroidism
This trial tests a new medicine called EXT608 for adults with hypoparathyroidism. It aims to see if this medicine can help manage calcium levels better than current treatments.
Buenos Aires, Buenos Aires F.D.Ages 18–65 - NCT07046559RecruitingPhase 1
Testing a new drug's safety in healthy volunteers
This trial is testing an experimental drug called LY4066708 in healthy people to see how safe it is and how the body processes it. It may help researchers understand if the drug can be used in future studies for conditions like Alzheimer's disease.
Holbeck, LeedsAges 18–65
Hear when a new Tolerance trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for tolerance?
- Yes. Clin2 currently lists 942 recruiting tolerance studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a tolerance trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a tolerance trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.